Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
https://www.fool.com/investing/2024/08/30/think-eli-lilly-stock-has-peaked-these-10-words/?source=iedfolrf0000001
Aug 30, 2024 - Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.
0
Eli Lilly’s Zepbound price cut comes with shocker for those on patient assistance
https://seekingalpha.com/news/4145247-eli-lilly-zepbound-price-cut-comes-with-shocker?source=feed_sector_healthcare
Aug 29, 2024 - Eli Lilly (LLY) cuts prices for weight loss drug Zepbound for self-paying customers but raises costs for patients in the assistance program. Read more here.
0
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
https://www.cnbc.com/2024/08/27/zepbound-eli-lilly-releases-new-cheaper-form-of-weight-loss-drug.html
Aug 27, 2024 - Eli Lilly is offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, respectively.
0
Weight loss drug developers slump as Eli Lilly slashes cost of some Zepbound doses
https://seekingalpha.com/news/4144285-weight-loss-drug-developers-slump-eli-lilly-slashes-cost-some-zepbound-doses?source=feed_sector_healthcare
Aug 27, 2024 - Drug companies developing weight loss drugs are down in trading after Eli Lilly reduces costs of Zepbound. Read more here.
0
If You Like Eli Lilly, Then You'll Love This Little-Known Specialty Manufacturing Stock
https://www.fool.com/investing/2024/08/24/if-you-like-eli-lilly-then-youll-love-this-little/?source=iedfolrf0000001
Aug 24, 2024 - Jacobs Solutions stands to be a beneficiary of the red-hot weight loss movement fueling the pharmaceutical market.
0
Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report
https://seekingalpha.com/news/4143531-eli-lilly-alzheimers-drug-face-uk-rejection?source=feed_sector_healthcare
Aug 24, 2024 - The UK is set to decline Eli Lilly's (LLY) Alzheimer's drug, donanemab, for use in the NHS following the rejection of Biogen's Leqembi. Read more here.
0
Eli Lilly to examine weight loss med Zepbound for immune disorders -- report
https://seekingalpha.com/news/4142053-eli-lilly-weight-loss-med-zepbound-under-investigation-immune-disorders-report?source=feed_sector_healthcare
Aug 20, 2024 - Eli Lilly is exploring the potential of tirzepatide as a treatment for immune diseases, with a trial planned to test its effectiveness with the company's Taltz. Read more here.
0
Eli Lilly, Organon expand distribution deal for migraine drug
https://seekingalpha.com/news/4141846-eli-lilly-organon-expand-distribution-deal-for-migraine-drug?source=feed_sector_healthcare
Aug 20, 2024 - Eli Lilly and Organon expand commercialization deal for migraine medicine Emgality in 11 new markets, with Organon as sole distributor.
0
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
https://www.fool.com/investing/2024/08/18/forget-mounjaro-eli-lillys-next-big-blockbuster-ha/?source=iedfolrf0000001
Aug 18, 2024 - Eli Lilly has a lot going for it.
0
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
https://www.fool.com/investing/2024/08/17/eli-lillys-top-glp-1-drugs-now-account-for-nearly/?source=iedfolrf0000001
Aug 17, 2024 - Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future.
0